Tiltan Pharma

Tiltan's drug combination

Nowadays, cancer treatments emerge increasingly as fighters of a multi-targeted battle, rather than a single targeted attack.

The solid tumor is not a "stand alone" entity in the body, but rather a mass of cancerous cells that constantly communicates with its close environment to attract oxygen, nutrients and growth factors for self-consumption, to grow and metastasize.

Thus, in attempt to attack a solid tumor, TL-118 drug combination therapy is applied against the tumor microenvironment elements:

- The cancerous cells

- The newly formed blood vessels that the tumor recruits to survive and grow

- The immune cells in the microenvironment that accompany the tumor entity



icon of a house icon of an envelope

Built by Badboy.co.il

© copyright 2015 Tiltan Pharma